Enliven Therapeutics, Inc. (ELVN)
$39.49-3.31%Close
SELLCRISIS · day 20
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.8B
- Beta
- 0.24
- P/E (TTM)
- -24.08
- Short % float
- 22.70%
- Days to cover
- 5.5
- SI change
- +20.1%
- 1W
- -6.84%
- 1M
- -27.45%
- vs SPY 1W
- -6.70%
- vs SPY 1M
- -29.95%
Industry peers
FMP comparable companies · ranked by market cap
- RVMDSELLRevolution Medicines, Inc.$40.1BRECOVERYQ 30$188.44-2.84%
- INCYSELLIncyte Corporation$22.0BBEARQ 13$108.62-2.46%
- EXELBUYExelixis, Inc.$15.0BBULLQ 10$59.51-0.52%
- RLAYSELLRelay Therapeutics, Inc.$3.8BRECOVERYQ 2$17.36-3.45%
- NUVBSELLNuvation Bio Inc.$1.6BCRISISQ 4$4.72-3.67%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.2BCRISISQ 15$13.95-15.71%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$11.31-4.23%
- TYRASELLTyra Biosciences, Inc.$1.1BCRISISQ 4$18.56-5.31%
- CGEMSELLCullinan Therapeutics, Inc.$867MCRISISQ 1$14.10-5.69%
- AVBPSELLArriVent BioPharma, Inc.$749MCRISISQ -6$16.09-2.25%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 20
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-11.1%
REV YoY-
ROE-18.5%
EPS YoY-
ROA-11.6%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-24.08
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.92
P/FCF-
EV/EBITDA-25.40
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.17
ALTMAN Z-
CURR RATIO64.07
ND/EBITDA-
BETA0.24
Company news
FAQ
- What is LOPJLB’s current signal on ELVN?
- LOPJLB’s latest quantitative signal on Enliven Therapeutics, Inc. (ELVN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ELVN in?
- Enliven Therapeutics, Inc. (ELVN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Enliven Therapeutics, Inc. (ELVN) do?
- Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, als…